NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03117049,Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52),https://clinicaltrials.gov/study/NCT03117049,,COMPLETED,"The purpose of study is to compare the efficacy and safety of ONO-4538 in combination with carboplatin, paclitaxel, and bevacizumab (ONO-4538 group) to placebo in combination with carboplatin, paclitaxel, and bevacizumab (placebo group) in chemotherapy-naïve subjects with stage IIIB/IV or recurrent non-squamous non-small cell lung cancer unsuitable for radical radiation in a multicenter, randomized, double-blind study.",YES,Non-Small Cell Lung Cancer,DRUG: ONO-4538|DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Bevacizumab|DRUG: Placebo,"Progression Free Survival (PFS) as Assessed by the Independent Radiology Review Committee (IRRC), PFS (as assessed by the IRRC) will be calculated using the following formula : PFS (days) = ""date when overall response is assessed as progressive disease (PD) or date of death (for any reason), whichever comes first"" - ""date of randomization"" + 1. Please refer to the protocol, in this study, tumor response will be evaluated by CT, etc. according to the RECIST 1.1 criteria., Approximately 32 months","Overall Survival (OS), Approximately 32 months|Objective Response Rate (ORR [as Assessed by the IRRC]), ORR represents the proportion of subjects whose best overall response was assessed as complete response (CR) or partial response (PR). Please refer to the protocol, in this study, tumor response will be evaluated by CT, etc. according to the RECIST 1.1 criteria., Approximately 32 months|Disease Control Rate (DCR [as Assessed by the IRRC]), DCR represents the proportion of subjects whose best overall response was assessed as CR, PR, or stable disease (SD). Please refer to the protocol, in this study, tumor response will be evaluated by CT, etc. according to the RECIST 1.1 criteria., Approximately 32 months|Duration of Response (DOR [as Assessed by the IRRC]), The lower and upper limits of 95% CI for the median are censored value in the both groups., Approximately 32 months|Best Overall Response (BOR [as Assessed by the IRRC]), Approximately 32 months",,Ono Pharmaceutical Co. Ltd,Bristol-Myers Squibb,ALL,"ADULT, OLDER_ADULT",PHASE3,550,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",ONO-4538-52,2017-06-13,2020-02-10,2023-12-04,2017-04-17,2022-04-26,2024-05-06,"Aichi Clinical Site2, Nagoya, Aichi, Japan|Aichi Clinical Site3, Nagoya, Aichi, Japan|Aichi Clinical Site4, Nagoya, Aichi, Japan|Aichi Clinical Site, Nagoya, Aichi, Japan|Aichi Clinical Site, Toyoake, Aichi, Japan|Aomori Clinical Site2, Hirosaki, Aomori, Japan|Aomori Clinical Site, Hirosaki, Aomori, Japan|Chiba Clinical Site, Yachiyo, Chiba, Japan|Ehime Clinical Site, Matsuyama, Ehime, Japan|Fukuoka Clinical Site, Iizuka, Fukuoka, Japan|Fukuoka Clinical Site, Kitakyushu, Fukuoka, Japan|Fukuoka Clinical Site, Koga, Fukuoka, Japan|Fukuoka Clinical Site, Kurume, Fukuoka, Japan|Fukushima Clinical Site, Kōriyama, Fukushima, Japan|Gunma Clinical Site, Ota, Gunma, Japan|Gunma Clinical Site, Shibukawa, Gunma, Japan|Hokkaido Clinical Site, Asahikawa, Hokkaido, Japan|Hokkaido Clinical Site2, Sapporo, Hokkaido, Japan|Hokkaido Clinical Site, Sapporo, Hokkaido, Japan|Hyogo Clinical Site, Akashi, Hyogo, Japan|Hyogo Clinical Site, Amagasaki, Hyogo, Japan|Hyogo Clinical Site, Himeji, Hyogo, Japan|Hyogo Clinical Site, Itami, Hyogo, Japan|Hyogo Clinical Site, Kobe, Hyogo, Japan|Hyogo Clinical Site, Nishinomiya, Hyogo, Japan|Hyogo Clinical Site, Takarazuka, Hyogo, Japan|Ibaraki Clinical Site, Higashiibaraki, Ibaraki, Japan|Ibaraki Clinical Site, Kasama, Ibaraki, Japan|Ibaraki Clinical Site, Tsuchiura, Ibaraki, Japan|Ishikawa Clinical Site2, Kanazawa, Ishikawa, Japan|Ishikawa Clinical Site3, Kanazawa, Ishikawa, Japan|Ishikawa Clinical Site, Kanazawa, Ishikawa, Japan|Iwate Clinical Site, Morioka, Iwate, Japan|Kanagawa Clinical Site, Isehara, Kanagawa, Japan|Kanagawa Clinical Site2, Kawasaki, Kanagawa, Japan|Kanagawa Clinical Site, Kawasaki, Kanagawa, Japan|Kanagawa Clinical Site, Sagamihara, Kanagawa, Japan|Kanagawa Clinical Site2, Yokohama, Kanagawa, Japan|Kanagawa Clinical Site3, Yokohama, Kanagawa, Japan|Kanagawa Clinical Site, Yokohama, Kanagawa, Japan|Kumamoto Clinical Site, Koshi, Kumamoto, Japan|Kyoto Clinical Site, Jōyō, Kyoto, Japan|Mie Clinical Site, Tsu, Mie, Japan|Miyagi Clinical Site, Natori, Miyagi, Japan|Miyagi Clinical Site, Sendai, Miyagi, Japan|Nagano Clinical Site, Matsumoto, Nagano, Japan|Nagasaki Clinical Site, Ōmura, Nagasaki, Japan|Nara Clinical Site, Ikoma, Nara, Japan|Niigata Clinical Site, Nagaoka, Niigata, Japan|Oita Clinical Site, Beppu, Oita, Japan|Oita Clinical Site, Yufu, Oita, Japan|Osaka Clinical Site2, Osaka, Osaka Clinical Site, Japan|Osaka Clinical Site, Habikino, Osaka, Japan|Osaka Clinical Site, Hirakata, Osaka, Japan|Osaka Clinical Site, Kishiwada, Osaka, Japan|Osaka Clinical Site, Osakasayama, Osaka, Japan|Osaka Clinical Site, Sakai, Osaka, Japan|Osaka Clinical Site, Toyonaka, Osaka, Japan|Saga Clinical Site, Ureshino, Saga, Japan|Saitama Clinical Site, Hidaka, Saitama, Japan|Saitama Clinical Site, Kitaadachi-gun, Saitama, Japan|Shimane Clinical Site, Izumo, Shimane, Japan|Shizuoka Clinical Site, Hamamatsu, Shizuoka, Japan|Shizuoka Clinical Site, Sunto-gun, Shizuoka, Japan|Tokyo Clinical Site2, Bunkyo-ku, Tokyo, Japan|Tokyo Clinical Site, Bunkyo-ku, Tokyo, Japan|Tokyo Clinical Site2, Bunkyō-Ku, Tokyo, Japan|Tokyo Clinical Site2, Chuo-ku, Tokyo, Japan|Tokyo Clinical Site, Chuo-ku, Tokyo, Japan|Tokyo Clinical Site, Fuchū, Tokyo, Japan|Tokyo Clinical Site, Itabashi-ku, Tokyo, Japan|Tokyo Clinical Site, Kiyose, Tokyo, Japan|Tokyo Clinical Site, Koto-ku, Tokyo, Japan|Tokyo Clinical Site, Meguro, Tokyo, Japan|Tokyo Clinical Site, Minato-ku, Tokyo, Japan|Tokyo Clinical Site, Mitaka-shi, Tokyo, Japan|Tokyo Clinical Site, Shibuya, Tokyo, Japan|Tokyo Clinical Site2, Shinjuku-Ku, Tokyo, Japan|Tokyo Clinical Site3, Shinjuku-Ku, Tokyo, Japan|Tokyo Clinical Site, Shinjuku-ku, Tokyo, Japan|Tokyo Clinical Site, Tachikawa, Tokyo, Japan|Tottori Clinical Site, Yonago, Tottori, Japan|Yamaguchi Clinical Site, Iwakuni, Yamaguchi, Japan|Chiba Clinical Site2, Chiba, Japan|Chiba Clinical Site, Chiba, Japan|Fukui Clinical Site, Fukui, Japan|Fukuoka Clinical Site2, Fukuoka, Japan|Fukuoka Clinical Site3, Fukuoka, Japan|Fukuoka Clinical Site4, Fukuoka, Japan|Fukuoka Clinical Site, Fukuoka, Japan|Gifu Clinical Site2, Gifu, Japan|Gifu Clinical Site, Gifu, Japan|Hiroshima Clinical Site2, Hiroshima, Japan|Hiroshima Clinical Site, Hiroshima, Japan|Kochi Clinical Site, Kochi, Japan|Kumamoto Clinical Site, Kumamoto, Japan|Kyoto Clinical Site, Kyoto, Japan|Nagasaki Clinical Site, Nagasaki, Japan|Niigata Clinical Site2, Niigata, Japan|Niigata Clinical Site, Niigata, Japan|Okayama Clinical Site2, Okayama, Japan|Okayama Clinical Site, Okayama, Japan|Osaka Clinical Site3, Osaka, Japan|Osaka Clinical Site, Osaka, Japan|Tokushima Clinical Site, Tokushima, Japan|Toyama Clinical Site2, Toyama, Japan|Toyama Clinical Site, Toyama, Japan|Wakayama Clinical Site, Wakayama, Japan|Yamaguchi Clinical Site, Yamaguchi, Japan|Oita Clinical Site, Ōita, Japan|Chungcheongbuk-do Clinical Site, Cheongju-si, Chungcheongbuk-do, Korea, Republic of|Gangwon-Do Clinical Site, Wŏnju, Gangwon-Do, Korea, Republic of|Gyeonggi-do Clinical Site2, Seongnam-si, Gyeonggi-do, Korea, Republic of|Gyeonggi-do Clinical Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Gyeonggi-do Clinical Site, Suwon, Gyeonggi-do, Korea, Republic of|Gyeongsangnam-do Clinical Site, Jinju-si, Gyeongsangnam-do, Korea, Republic of|Busan Clinical Site, Busan, Korea, Republic of|Daegu Clinical Site, Daegu, Korea, Republic of|Incheon Clinical Site, Incheon, Korea, Republic of|Seoul Clinical Site2, Seoul, Korea, Republic of|Seoul Clinical Site3, Seoul, Korea, Republic of|Seoul Clinical Site4, Seoul, Korea, Republic of|Seoul Clinical Site5, Seoul, Korea, Republic of|Seoul Clinical Site6, Seoul, Korea, Republic of|Seoul Clinical Site, Seoul, Korea, Republic of|Changhua Clinical Site, Changhua, Taiwan|Chiayi Clinical Site, Chiayi City, Taiwan|Kaohsiung Clinical Site2, Kaohsiung, Taiwan|Kaohsiung Clinical Site3, Kaohsiung, Taiwan|Kaohsiung Clinical Site, Kaohsiung, Taiwan|Taichung Clinical Site, Taichung, Taiwan|Tainan Clinical Site, Tainan, Taiwan|Taipei Clinical Site2, Taipei, Taiwan|Taipei Clinical Site, Taipei, Taiwan|Taoyuan Clinical Site, Taoyuan, Taiwan","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/49/NCT03117049/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/49/NCT03117049/SAP_001.pdf"
